Glenmark Pharmaceuticals Limited

NSEI:GLENMARK Stock Report

Market Cap: ₹462.6b

Glenmark Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 2/6

Glenmark Pharmaceuticals is a dividend paying company with a current yield of 0.15%.

Key information

0.2%

Dividend yield

-0.003%

Buyback Yield

Total Shareholder Yield0.1%
Future Dividend Yield0.2%
Dividend Growth0.2%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per share₹2.500
Payout ratio-4%

Recent dividend and buyback updates

Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Sep 06
Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Recent updates

Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Dec 17
Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

Oct 26
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Sep 21
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Sep 06
Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 06
Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Jun 16
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08
Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Mar 09
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: GLENMARK's dividends per share have been stable in the past 10 years.

Growing Dividend: GLENMARK's dividend payments have increased over the past 10 years.


Dividend Yield vs Market

Glenmark Pharmaceuticals Dividend Yield vs Market
How does GLENMARK dividend yield compare to the market?
SegmentDividend Yield
Company (GLENMARK)0.2%
Market Bottom 25% (IN)0.2%
Market Top 25% (IN)1.1%
Industry Average (Pharmaceuticals)0.7%
Analyst forecast (GLENMARK) (up to 3 years)0.2%

Notable Dividend: GLENMARK's dividend (0.15%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.24%).

High Dividend: GLENMARK's dividend (0.15%) is low compared to the top 25% of dividend payers in the Indian market (1.1%).


Earnings Payout to Shareholders

Earnings Coverage: GLENMARK is paying a dividend but the company is unprofitable.


Cash Payout to Shareholders

Cash Flow Coverage: GLENMARK is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 07:42
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Glenmark Pharmaceuticals Limited is covered by 55 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Ganeshram JayaramanAvendus Spark